Bristol-myers Squibb Compnay

Vivekananda M Vrudhula

John E Macor

Joanne J Bronson

Bireshwar Dasgupta

Gene Michael Dubowchik

Carolyn Diane Dzierba

Susheel Jethanand Nara

Ramkumar Rajamani

Senliang Pan

Maheswaran Sivasamban Karatholuvhu

Richard A Hartz

Dolatrai M Vyas

Vijay T Ahuja

Dmitry S Zuev

Katerina Leftheris

Chunjian Liu

Guanglin Luo

James M Lin

Prasanna Sivaprakasam

George O Tora

Andrew P Degnan

Valentin K Gribkoff

Ling Chen

Tarun Kumar Maishal

Jonathan L Ditta

Derek John Denhart

Swanee E Jacutin-Porte

Christopher G Boissard

Valentin Kala Gribkoff

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

Heterocyclic kinase inhibitors

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3. 

GSK-3 inhibitors

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1. 

Aryl amide-based kinase inhibitors

Aryl ether-base kinase inhibitors

Aryl lactam kinase inhibitors

The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.

Pyrazinone modulator of corticotropin-releasing factor receptor activity

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders. 

Substituted heterocyclic ethers and their use in CNS disorders

The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF. 

[object Object]

Compounds having the Formula (I), including pharmaceutically acceptable salts thereof, wherein at least one of X, Xor Xis and any remaining X, Xor Xis hydrogen, which are useful as kinase inhibitors, wherein R, R, R, R, R, R, A, Aand m are as described herein.

Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors

The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor ('CRF receptor') useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

Imidazolyl derivatives as corticotropin releasing factor inhibitors

Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives having the general formulawherein R, R, R, R, Rand R, are as defined herein, or a non-toxic pharmaceutically acceptable salt, solvate or prodrug thereof. The atropisomers can modulate the large conductance calcium-activated Kchannels and are useful in the treatment of disorders which are responsive to the opening of the potassium channels. In addition, the atropisomers can be stable, i.e., do not interconvert, for periods of up to one month, or more.

Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives

The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor ('CRF receptor')useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

The present invention relates to the design, synthesis, and the peptidyl-prolyl isomerase (PPIase or rotamase) inhibitory activity of novel &agr;,&agr;-difluoroacetamido compounds that are neurotrophic agents (i.e. compounds capable of stimulating growth or proliferation of nervous tissue) and that bind to immunophilins such as FKBP12 and inhibit their rotamase activity. This invention also relates to pharmaceutical compositions comprising these compounds.

Growing community of inventors

Killingworth, CT, United States of America

Vivekananda M Vrudhula